Archive




Volume 7, Issue 4, August 2019, Page: 68-74
The Adverse Effects of Tamsulosin in Men with Benign Prostatic Hyperplasia, a Review of the Literature
Nathan Walter Leibacher, Urogenital Research Unit, Rio de Janeiro State University, Rio de Janeiro, Brazil
Marcello Henrique Araujo Da Silva, Urogenital Research Unit, Rio de Janeiro State University, Rio de Janeiro, Brazil
Received: Aug. 14, 2019;       Accepted: Aug. 22, 2019;       Published: Sep. 11, 2019
DOI: 10.11648/j.ajls.20190704.11      View  51      Downloads  28
Abstract
In the United States, tamsulosin is the most prescribed drug for benign prostatic hyperplasia (BPH) treatment. However, less is known about the adverse effects and mechanism of action of the drug in the organism. So, the aim of this review is to evaluate the benefits and harms of tamsulosin therapy in patients with BPH. A literature analysis was realized using the database of the National Center for Biotechnology Information (NCBI) MEDLINE®. The data collection was carried out in a retrospective of 10 years from 2008. Thus, we considered some measurements parameters used in different studies for a reliable comparison of the works. Tamsulosin has been characterized as an effective treatment for BPH. However, some studies demonstrate that the epithelial elements remain proliferative even after the administration of the drug and may be involved in the continuous growth of the gland. Also, tamsulosin can directly impact on the ejaculation process, cognitive functions and mental health of men. BPH affects approximately 50% of men between 50 and 60 years old. Beyond that, 90% of men in their eighth decade of life will present anatomical evidence of BPH. Therefore, the treatment with tamsulosin, an α1-adrenergic antagonist that promotes the relaxation of the prostate smooth muscle, is essential to diminish the gland size and restore the urinary flow. However, its administration must be assessed for a better response and lower risk of adverse effects in those patients.
Keywords
Tamsulosin, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Adverse Effects, Alpha Antagonist, Prostate
To cite this article
Nathan Walter Leibacher, Marcello Henrique Araujo Da Silva, The Adverse Effects of Tamsulosin in Men with Benign Prostatic Hyperplasia, a Review of the Literature, American Journal of Life Sciences. Special Issue: Advances in Urology and Nephrology in the 21st Century. Vol. 7, No. 4, 2019, pp. 68-74. doi: 10.11648/j.ajls.20190704.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug; 43 (3): 289-97.
[2]
Da Silva MHA, De Souza DB. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol. 2019; 11: 1-8.
[3]
Black L, Naslund MJ, Gilbert TD, et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care. 2006 Mar; 12 (4 Suppl): S99-S110.
[4]
Lepor H, Tang R, Meretyk S, et al. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993 Mar; 149 (3): 640-2.
[5]
La Vignera S, Condorelli RA, Russo GI, et al. Endocrine control of benign prostatic hyperplasia. Andrology. 2016 May; 4 (3): 404-11.
[6]
Shapiro E, Becich MJ, Hartanto V, et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992 May; 147 (5): 1293-7.
[7]
Toivanen R, Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell-type specification. Development. 2017 Apr 15; 144 (8): 1382-98.
[8]
Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 2017 Mar; 20 (1): 17-22.
[9]
Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. Int Urol Nephrol. 2016 May; 48 (5): 645-56.
[10]
Herberts M, Butcher M, Kohler T. The Effect of LUTS/BPH and Treatments on Ejaculatory Function. Curr Urol Rep. 2016 Jul; 17 (7): 48.
[11]
Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009 Apr; 181 (4): 1779-87.
[12]
Nickel JC, Aaron L, Barkin J, et al. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J. 2018 Oct; 12 (10): 303-12.
[13]
Wein AJ, Coyne KS, Tubaro A, et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3: 33-41.
[14]
McVary, Kevin T. et al. Surgical Management Of Lower Urinary Tract Symptoms Attributed To Benign Prostatic Hyperplasia: Aua Guideline Amendment 2019. J Urol, p. 10.1097/JU, 2019.
[15]
Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015 Jun; 67 (6): 1099-109.
[16]
Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol. 2018 Sep; 200 (3): 612-9.
[17]
Gratzke, Christian et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, v. 67, n. 6, p. 1099-1109, 2015.
[18]
Karavitakis M, Kyriazis I, Omar MI, et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. 2019 Feb 14.
[19]
Da Silva MHA, Costa WS, FJ BS, et al. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018 Sep-Oct; 20 (5): 505-10.
[20]
Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011 Nov; 8 (11): 3066-74.
[21]
Fuentes AV, Pineda MD, Venkata KCN. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. Pharmacy (Basel). 2018 May 14; 6 (2): 43.
[22]
Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002; 19 (2): 135-61.
[23]
Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall; 9 (4): 181-90.
[24]
Bird ST, Delaney JA, Brophy JM, et al. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within the patient methodology. BMJ. 2013 Nov 5; 347: f6320.
[25]
Royuela M, de Miguel MP, Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol. 2001 Mar; 168 (3): 447-54.
[26]
Prezioso D, Denis LJ, Klocker H, et al. Estrogens and aspects of prostate disease. Int J Urol. 2007 Jan; 14 (1): 1-16.
[27]
Fukami M, Homma K, Hasegawa T, et al. Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. Dev Dyn. 2013 Apr; 242 (4): 320-9.
[28]
Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003 Apr; 61 (4 Suppl 1): 2-7.
[29]
Chughtai B, Forde JC, Thomas DD, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 5; 2: 16031.
[30]
Kim JJ, Han DH, Sung HH, et al. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo-controlled trial. Int J Urol. 2014 Jul; 21 (7): 677-82.
[31]
Nash DT. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol. 1990 Nov; 13 (11): 764-72.
[32]
Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta-analysis. Chin Med J (Engl). 2010 Jan 20; 123 (2): 234-8.
[33]
Matsushita T, Hasegawa T, Nakano M, et al. The Effect of Tamsulosin Treatment on Erectile Functions in Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostate Hyperplasia: Correlation between Improvement of LUTS and Erectile Function. Low Urin Tract Symptoms. 2011 Apr; 3 (1): 15-8.
[34]
Aslan G, Cavus E, Karas H, et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl. 2006 May-Jun; 52 (3): 155-62.
[35]
Yoshida M, Inadome A, Masunaga K, et al. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia. Neurourol Urodyn. 2010 Sep; 29 (7): 1276-81.
[36]
Kim KS, Jang EY, Kim YT, et al. Tamsulosin Treatment Affecting Patient-reported Outcomes in Benign Prostatic Hyperplasia-associated Depressive Symptoms. Urology. 2016 Jan; 87: 172-7.
[37]
Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007; 10 (2): 149-54.
[38]
Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5alpha-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013 Nov; 138: 10-6.
[39]
Frankel JK, Duan Y, Albertsen PC. Is Tamsulosin Linked to Dementia in the Elderly? Curr Urol Rep. 2018 Jul 3; 19 (9): 69.
[40]
Duan Y, Grady JJ, Albertsen PC, et al. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018 Mar; 27 (3): 340-8.
[41]
Becher KF, Madersbacher S, Michel MC. Do benign prostatic hyperplasia drugs affect mood or cognition?. Urologe A. 2019 Mar; 58 (3): 248-53.
[42]
Choi JH, Hwa JS, Kam SC, et al. Effects of tamsulosin on premature ejaculation in men with benign prostatic hyperplasia. World J Mens Health. 2014 Aug; 32 (2): 99-104.
[43]
Kim SW, Lee WC, Kim MT, et al. Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Korean J Urol. 2013 Oct; 54 (10): 697-702.
[44]
Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005 Jun; 47 (6): 824-37.
[45]
Yu, Hong‐Jeng, et al. Non‐inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU int. 108.11 (2011): 1843-1848.
[46]
Seo, Deok Ha, Sung Chul Kam, Jae Seog Hyun. Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function. Korean J Urol. 52.1 (2011): 49-54.
[47]
Shelbaia, Ahmed, et al. Effect of selective alpha-blocker tamsulosin on erectile function in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Urol 82.1 (2013): 130-135.
[48]
Pande, Satabdi, Avijit Hazra, and Anup Kumar Kundu. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol. 46.6 (2014): 601.
[49]
Traish, Abdulmaged M., et al. Finasteride, not tamsulosin, increases the severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 23.3 (2015): 85-96.
[50]
Dimitropoulos, Konstantinos, and Stavros Gravas. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol. 8.1 (2016): 19-28.
[51]
Fawzi, Amr, et al. Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled trial. Arab J Urol.15.1 (2017): 53-59.
Browse journals by subject